FUTURE THERAPEUTIC TARGETS IN MANAGEMENT OF AUTOIMMUNE SKIN DISEASES

Cover Page


Cite item

Full Text

Abstract

Pemphigus is a severe, potentially fatal bullous skin disease, caused by desmoglein autoantibody production and immune-mediated regulation of T-cells subsets. Conventional therapy including systemic corticosteroids with or without other immunosupressants causes numerous adverse effects and becomes inefficient in refractory patients. In this work, the authors showed a modern view on the pathogenesis of pemphigus. This article describes the detailed action mechanism of rituximab, a chimeric monoclonal antibody directed against CD20 antigen of B-cells. The authors conduct the results of meta-analyses of rituximab’s efficiency in pemphigus patients. Moreover, in this article, the authors consider new promising treatment options and potential targets for biological therapy of pemphigus diseases.

About the authors

A. A. Kubanova

State Research Centre of Dermatovenereology and Cosmetology, Moscow, Russian Federation

Author for correspondence.
Email: info@cnikvi.ru

доктор медицинских наук, академик РАН, директор ГНЦДК
Адрес: 107076, Москва, ул. Короленко, д. 3, стр. 6, тел.: +7 (499) 785-20-15

Russian Federation

A. E. Karamova

State Research Centre of Dermatovenereology and Cosmetology, Moscow, Russian Federation

Email: karamova@cnikvi.ru

кандидат медицинских наук, ведущий научный сотрудник отдела дерматологии
ГНЦДК
Адрес: 107076, Москва, ул. Короленко, д. 3, стр. 6, тел.: +7 (499) 785-20-96

Russian Federation

A. A. Kubanov

State Research Centre of Dermatovenereology and Cosmetology, Moscow, Russian Federation

Email: alex@cnikvi.ru

доктор медицинских наук, профессор, заместитель директора ГНЦДК
Адрес: 107076, Москва, ул. Короленко, д. 3, стр. 6, тел.: +7 (499) 785-20-83

Russian Federation

References

  1. Nasonov E.L. Prospects for the use of rituximab in autoimmune diseases of human. RMZh = Russian medical journal. 2007; 15 (26):1958—1963
  2. Kubanov A.A., Abramova T.V. Vestnik dermatologii i venerologii = Bulletin of dermatology and venereology. 2014; 4: 19–27.
  3. Tamgadge S.,Tamgadge A., Bhatt D.M., Bhalerao S, Pereira T. et al. Contemp. Clin. Dent. 2011; 2: 134–137.
  4. Groves R.W. Clin. Med. 2009; 9 (4): 371–375.
  5. Chmurova N., Svecova D. Bratislava Med. J. 2009; 110 (8): 500–503.
  6. Langan S.M., Smeeth L., Hubbard R., Fleming K.M., Smith C.J.P., West J. BMJ. 2008; 337: a180.
  7. Mimouni D., Bar H., Gdalevich M., Katzenelson V., David M. J. Eur. Acad. Dermatology Venereol. 2010; 24: 947–952.
  8. Yan L., Wang J.-M., Zeng K. Br. J. Dermatol. 2012; 167 (4): 768–777.
  9. Mortazavi H., Amirzargar A.A., Esmaili N., Toofan H., Ehsani A.H., Hosseini S.H. J. Dermatol. 2013; 40 (4): 244–248.
  10. Pan M., Zhu H., Xu R. J. Dermatol. 2015; 42 (1): 11–17.
  11. Meyer N., Misery L. Autoimmun. Rev. 2010; 9 (5): A379–A382
  12. Thomas M., Paul C., Berard E., Fortenfant F., Mazereeuw-Hautier J., Livideanu C. et al. Dermatology. 2010; 220 (2): 97–102.
  13. Adaskevich V.P., Kozin V.M. Kozhnye i venericheskie bolezni [Skin and Venereal Diseases]. Moscow, Med. lit., 2006. 672 p.
  14. Satyam A., Khandpur S., Sharma V.K., Sharma A. Immunol. Invest. 2009; 38 (6): 498–509.
  15. Grando S.A. Autoimmunity. 2012; 45 (1): 7–35.
  16. Pfutze M., Niedermeier A., Hertl M., Eming R. Eur. J. dermatology. 2007; 17 (1): 4–11.
  17. Hertl M., Eming R., Veldman C. J. Clin. Invest. 2006; 116 (5): 1159–1166.
  18. Wada N., Nishifuji K., Yamada T., Kudoh J., Shimizu N., Matsumoto M. et al. J. Invest. Dermatol. 2011; 131 (2): 410–417.
  19. Kim J.M., Rasmussen J.P., Rudensky A.Y. Nat. Immunol. 2007; 8 (2): 191–197.
  20. Zhu H., Chen Y., Zhou Y., Wang Y., Zheng J., Pan M. J. Clin. Immunol. 2012; 32 (1): 114–123.
  21. Giordano C.N., Sinha A.A. Autoimmunity. 2012; 45 (6): 427–439.
  22. Arakawa M., Dainichi T., Yasumoto S., Hashimoto T. J. Dermatol. Sci. 2009; 53 (3): 228–231.
  23. Xu R.-C., Li W.-P., Zhao X.-Q., Yuan H.-J., Zheng J., Pan M. Eur. J. Dermatol. 2013; 23 (6): 795–802.
  24. Thorn G.W., Forsham P.H., Frawley T.F., Hill, S.R., Roche, M., Staehelin D.W. et al. N. Engl. J. Med. 1950; 242 (22): 865–872.
  25. Mutasim D.F. Ther. Clin. Risk Manag. 2007; 3 (1): 29–40.
  26. Ruocco E., Wolf R., Ruocco V., Brunetti G., Romano F., Lo Schiavo A. Clin. Dermatol. 2013; 31 (4): 382–390.
  27. Feldman R.J., Ahmed A.R. Clin. Immunol. 2011; 7 (4): 529–541.
  28. Lunardon L., Payne A.S. G. Ital. Dermatol. Venereol. 2012; 147 (3): 269–276.
  29. Motta G., Cea M., Moran E., Carbone F., Augusti V., Patrone F. Clin Dev Immunol. 2010; 428253.
  30. Ahmed A.R., Shetty S. Autoimmun. Rev. 2015; 14 (4): 323–331.
  31. Lunardon L., Tsai K.J., Propert K.J., Fett N., Stanley J.R., Werth V.P., Tsai D.E. et al. Arch. Dermatol. 2012; 148 (9): 1031–1036.
  32. Colliou N., Picard D., Caillot F., Calbo S., Le Corre S., Lim A. et al. Sci. Transl. Med. 2013; 5 (175): 175ra30.
  33. Hertl M., Jedlickova H., Karpati S., Marinovic B., Uzun S., Yayli S.J. et al. Eur. Acad. Dermatol. Venereol. 2015; 29 (3): 405–414.
  34. Vojáčková N., Fialová J., Vaňousová D., Hercogová J. Dermatol. Ther. 2012; 25 (1): 95–97.
  35. Fiorentino D.F., Garcia M.S., Rehmus W., Kimball, A.B. Arch. Dermatol. 2011; 147 (1): 117–118.
  36. Howell S.M., Bessinger G.T., Altman C.E., Belnap C.M. J. Am. Acad. Dermatol. 2005; 53 (3): 541–543.
  37. Jacobi A., Shuler G., Hertl M. Br. J. Dermatol. 2005; 153 (2): 448–449.
  38. Lin M.-H., Hsu C.-K., Lee J.Y.-Y. Arch. Dermatol. 2005; 141 (6): 680–682.
  39. Pardo J., Mercader P., Mahiques L., Sanchez-Carazo J.L., Oliver V., Fortea J.M. 2005; 153 (1): 222–223.
  40. Ludwig R.J., Schmidt E. G. Ital. Dermatol. Venereol. 2009; 144 (4): 339–349.
  41. Church L.D., McDermott M.F. Curr. Opin. Mol. Ther. 2009; 11 (1): 81–89.
  42. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalAppli-cations/TherapeuticBiologicApplications/ucm080650.htm (accessed: 08.04.2015).
  43. Choy E.H.S., Isenberg D.A., Garrood T., Farrow S., Ioannou Y., Bird H. et al. Arthritis Rheum. 2002; 46 (12): 3143–3150.
  44. Actemra (tocilizumab) FDA Approval History - Drugs.com [Online]. Available at: http://www.drugs.com/history/actemra.html (accessed: 06.03.2015).
  45. Borish L.C., Nelson H.S., Lanz M.J., Claussen L., Whitmore J.B., Agosti J.M. et al. Am. J. Respir. Crit. Care Med. 1999; 160 (6): 1816–1823.
  46. Hart T.K., Blackburn M.N., Brigham-Burke M., Dede K., Al-Mahdi N., Zia-Amirhosseini P. et al. Clin. Exp. Immunol. 2002; 130 (1): 93–100.
  47. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/ucm109106.htm (accessed: 08.04.2015).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies